Trial Profile
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-10
- Sponsors Eli Lilly and Company
- 14 Apr 2021 Results (n=1042) of systematic review and meta-analysis of pooled data from randomized controlled trials (AWARD-10, DURATION-8 and SUSTAIN 9 trials) assessing the safety and efficacy of addition of a glucagon-like peptide-1 receptor agonists (GLP-1RAs) on a Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) compared to SGLT-2i alone in patients with type 2 diabetes mellitus, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
- 26 Feb 2018 Results published in an Eli Lilly Media Release.
- 26 Feb 2018 According to an Eli Lilly media release, data were published online first in The Lancet Diabetes & Endocrinology.